Literature DB >> 27130345

Carbamazepine and oxcarbazepine: reflections after an oxcarbazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap.

Jamil Poletti-Jabbour1, Andrés Wiegering-Rospigliosi1, Reneé Pereyra-Elías2, Carmen Cecilia Elías-Barrera3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27130345     DOI： 10.1007/s00228-016-2066-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  10 in total

1.  AAN-EFNS guidelines on trigeminal neuralgia management.

Authors:  G Cruccu; G Gronseth; J Alksne; C Argoff; M Brainin; K Burchiel; T Nurmikko; J M Zakrzewska
Journal:  Eur J Neurol       Date:  2008-08-21       Impact factor: 6.089

2.  Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Hiroshi Chantaphakul; Thanomsak Sanon; Jettanong Klaewsongkram
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

Review 3.  Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability.

Authors:  Jonathan S E Hellewell
Journal:  J Affect Disord       Date:  2002-12       Impact factor: 4.839

Review 4.  EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.

Authors:  N Attal; G Cruccu; R Baron; M Haanpää; P Hansson; T S Jensen; T Nurmikko
Journal:  Eur J Neurol       Date:  2010-04-09       Impact factor: 6.089

5.  Safety and tolerability of oxcarbazepine in elderly patients with epilepsy.

Authors:  Ekrem Kutluay; Kevin McCague; Joseph D'Souza; Ahmad Beydoun
Journal:  Epilepsy Behav       Date:  2003-04       Impact factor: 2.937

Review 6.  Rationale and evidence for the use of oxcarbazepine in neuropathic pain.

Authors:  Enrique Carrazana; Imao Mikoshiba
Journal:  J Pain Symptom Manage       Date:  2003-05       Impact factor: 3.612

Review 7.  Oxcarbazepine for refractory epilepsy: systematic review of the literature.

Authors:  Humberto Saconato; Gilmar Fernandes do Prado; Maria Eduarda dos Santos Puga; Alvaro Nagib Atallah
Journal:  Sao Paulo Med J       Date:  2009       Impact factor: 1.044

8.  Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012.

Authors:  Lars Bendtsen; Steffen Birk; Helge Kasch; Karen Aegidius; Per Schmidt Sørensen; Lise Lykke Thomsen; Lars Poulsen; Mary-Jette Rasmussen; Christina Kruuse; Rigmor Jensen
Journal:  J Headache Pain       Date:  2012-02       Impact factor: 7.277

9.  Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).

Authors:  E Besi; D R Boniface; R Cregg; J M Zakrzewska
Journal:  J Headache Pain       Date:  2015-09-03       Impact factor: 7.277

10.  Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain.

Authors:  Giulia Di Stefano; Silvia La Cesa; Andrea Truini; Giorgio Cruccu
Journal:  J Headache Pain       Date:  2014-06-09       Impact factor: 7.277
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.